首页 › 基金 › GILEAD SCIENCES, INC. › XLO

GILEAD SCIENCES, INC. 对 XLO 的持仓历史

Xilio Therapeutics Inc. · 医疗保健

GILEAD SCIENCES, INC. 在 Q3 2026 的 13F 申报中披露持有 XLO(Xilio Therapeutics Inc.)650,389 股,市值约 US$5.9M,约占其申报组合的 0.40%,在其申报持仓中市值排名第 5 位。 GILEAD SCIENCES, INC. 最近 8 个申报季度中有 8 个季度披露了 XLO 持仓,最早可追溯至 Q4 2024。

最新持仓 (Q3 2026)650.39K 股
申报持仓市值$5.89M
组合权重0.40%
首次申报Q4 2024
最近变动持有
更新于2026-11-06

最后更新: 2026-11-06 · 来源: SEC EDGAR Form 13F-HR

GILEAD SCIENCES, INC. 对 XLO 的持仓演变

GILEAD SCIENCES, INC. 于 Q4 2024 首次披露 XLO 持仓:9,105,451 股(约 US$8.7M)。 在 8 次申报中,GILEAD SCIENCES, INC. 0 次增持、1 次减持、6 次保持不变。 最近一期申报(Q3 2026)显示持股 650,389 股、市值约 US$5.9M。 持仓曾出现大幅变动:Q1 2026 减持约 93% (随后一个季度股价上涨 14%)。

逐季持仓明细

季度股数金额变化
Q4 2024 9.11M $8.70M 新进
Q1 2025 9.11M $6.60M 持有
Q2 2025 9.11M $6.19M 持有
Q3 2025 9.11M $7.67M 持有
Q4 2025 9.11M $5.83M 持有
Q1 2026 650.39K $5.47M 减持
Q2 2026 650.39K $6.23M 持有
Q3 2026 650.39K $5.89M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 XLO 与 13F 数据

XLO(Xilio Therapeutics Inc.)属于医疗保健行业。我们追踪的基金中还有 24 只申报持有 XLO,申报仓位最大的包括:Bain Capital Life Sciences Investors, LLC (US$6.4M), Frazier Life Sciences Management, L.P. (US$4.0M), Stonepine Capital Management, LLC (US$2.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 XLO 的基金

查看 XLO 的全部基金持有人 →

常见问题

How long has GILEAD SCIENCES, INC. held XLO?

GILEAD SCIENCES, INC. has disclosed XLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is GILEAD SCIENCES, INC.'s current position in XLO?

As of Q3 2026, GILEAD SCIENCES, INC. holds 650.39K shares of XLO (Xilio Therapeutics Inc.), valued at $5.89M, representing 0.40% of its reported portfolio and ranking #5.

Has GILEAD SCIENCES, INC. been buying or selling XLO?

In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in XLO.

Which other funds hold XLO?

Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, Frazier Life Sciences Management, L.P., Stonepine Capital Management, LLC, among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.